^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD3 agonist

    Related drugs:
    1d
    CUREFL03: Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma (clinicaltrials.gov)
    P2, N=80, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD20 positive
    |
    zeprumetostat (SHR-2554) • Lunsumio (mosunetuzumab-axgb)
    1d
    PrE0512: Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer (clinicaltrials.gov)
    P3, N=430, Not yet recruiting, PrECOG, LLC.
    New P3 trial
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    Imfinzi (durvalumab) • Imdelltra (tarlatamab-dlle)
    1d
    Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More Treatment (clinicaltrials.gov)
    P2, N=90, Not yet recruiting, SWOG Cancer Research Network
    New P2 trial
    |
    CD19 (CD19 Molecule) • KMT2A (Lysine Methyltransferase 2A)
    |
    clonoSEQ®
    |
    cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • Revuforj (revumenib) • leucovorin calcium • mercaptopurine • Asparlas (calaspargase pegol-mknl) • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)
    1d
    MP0533-CP101: Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic Syndrome (clinicaltrials.gov)
    P1/2, N=249, Active, not recruiting, Molecular Partners AG | Recruiting --> Active, not recruiting | Trial completion date: Dec 2029 --> May 2027 | Trial primary completion date: Dec 2027 --> May 2026
    Enrollment closed • Trial completion date • Trial primary completion date • First-in-human
    |
    Venclexta (venetoclax) • azacitidine • Gazyva (obinutuzumab) • MP0533
    1d
    PEPN1812: Flotetuzumab for the Treatment of Pediatric Recurrent or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
    P1, N=16, Active, not recruiting, Children's Oncology Group | Trial completion date: Mar 2026 --> Dec 2026
    Trial completion date
    |
    cytarabine • flotetuzumab (MGD006) • Starasid (cytarabine ocfosfate)
    1d
    DAREON-7: DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers (clinicaltrials.gov)
    P1, N=55, Active, not recruiting, Boehringer Ingelheim | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    cisplatin • carboplatin • etoposide IV • obrixtamig (BI 764532)
    2d
    A Clinical Trial of MK-1045 and Rituximab in People With Follicular Lymphoma (MK-1045-007) (clinicaltrials.gov)
    P2/3, N=960, Not yet recruiting, Merck Sharp & Dohme LLC
    New P2/3 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • Truxima (rituximab-abbs) • Belrapzo (bendamustine RTD)
    2d
    Forimtamig: a potent GPRC5D-targeted bispecific antibody in multiple myeloma. (PubMed, Ann Med Surg (Lond))
    When combined with standard agents such as daratumumab, pomalidomide, or cereblon E3 ligase modulatory drugs, forimtamig has shown improved tumor clearance and reduced relapse rates. Currently undergoing phase 1 trials, forimtamig is being evaluated both as monotherapy and in combination regimens. Its high potency, favorable safety, and durable immune engagement make it a promising candidate in the evolving treatment landscape of multiple myeloma.
    Journal
    |
    CRBN (Cereblon)
    |
    Darzalex (daratumumab) • pomalidomide • forimtamig (RG6234)
    2d
    Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis (clinicaltrials.gov)
    P1, N=90, Recruiting, Regeneron Pharmaceuticals | Trial completion date: Jul 2028 --> Sep 2029 | Trial primary completion date: Jul 2028 --> Sep 2029
    Trial completion date • Trial primary completion date
    |
    Ordspono (odronextamab) • vonsetamig (REGN5459)
    2d
    Radio-GLO: Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell Lymphoma (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Olivia Newton-John Cancer Research Institute
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1) • IL4 (Interleukin 4)
    |
    Gazyva (obinutuzumab) • Columvi (glofitamab-gxbm)
    3d
    Gineco-ov133b: REGENOVAR: A Phase I/II Study of Ubamatamab Plus Carboplatin, Paclitaxel, and Bevacizumab as Salvage Therapy in Ovarian Cancer with Poor Response to First-Line Chemotherapy. (2025-524232-20-00)
    P1/2, N=43, Not yet recruiting, Asso De Recherche Cancers Gynecologiques
    New P1/2 trial
    |
    HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    HRD
    |
    Avastin (bevacizumab) • carboplatin • paclitaxel • ubamatamab (REGN4018) • Neupogen (filgrastim)
    5d
    MajesTEC-2: A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma (clinicaltrials.gov)
    P1, N=140, Active, not recruiting, Janssen Research & Development, LLC | Trial primary completion date: Apr 2027 --> Oct 2025
    Trial primary completion date
    |
    lenalidomide • bortezomib • Darzalex (daratumumab) • pomalidomide • Ogsiveo (nirogacestat) • Tecvayli (teclistamab-cqyv)